Free Biopharma Daily Stock Updates - 10/01/21

$XBI $126 +0.5%

---

Pipeline Updates

$MCRB +4% SERES THERAPEUTICS PRESENTS LATE-BREAKING DATA FROM SER-109 PHASE 3 ECOSPOR III STUDY IN RECURRENT C. DIFFICILE INFECTION AT IDWEEK2021

$ADPT -2% Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme Disease

INCY -1% Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo

$GILD -2% U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

$BBIO +2% bridgebio pharma announces updated phase 2b data for encaleret in autosomal dominant hypocalcemia type 1 (adh1) demonstrating blood and urine calcium normalization in trial participants

$CTIC -3% CTI BioPharma Announces Topline Data from Final Analysis of the PRE-VENT Clinical Trial Evaluating Pacritinib as a Treatment for Severe COVID-19

$RGNX -4% REGENXBIO PRESENTS POSITIVE INITIAL DATA FROM PHASE II AAVIATE® TRIAL OF RGX-314 FOR THE TREATMENT OF WET AMD USING SUPRACHOROIDAL DELIVERY AND PROVIDES TRIAL UPDATE AT RETINA SOCIETY 54TH ANNUAL SCIENTIFIC MEETING

$CHRS +3% Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review

$HGEN -1% Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK’s MHRA

$OMER -38% OMEROS PROVIDES REGULATORY UPDATE ON BIOLOGICS LICENSE APPLICATION FOR NARSOPLIMAB IN THE TREATMENT OF HSCT-TMA

$PGEN +3% Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

$BTNX -7% BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients

Financial & Business Updates

$ANIX -1% Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

---

Posted by DV